Japan Inhalable Biologics Market Size & Outlook, 2025-2030
Related Markets
Japan inhalable biologics market highlights
- The Japan inhalable biologics market generated a revenue of USD 204.2 million in 2024 and is expected to reach USD 574.6 million by 2030.
- The Japan market is expected to grow at a CAGR of 18.8% from 2025 to 2030.
- In terms of segment, peptides and proteins was the largest revenue generating type in 2024.
- RNAi-based Therapeutics is the most lucrative type segment registering the fastest growth during the forecast period.
Inhalable biologics market data book summary
| Market revenue in 2024 | USD 204.2 million |
| Market revenue in 2030 | USD 574.6 million |
| Growth rate | 18.8% (CAGR from 2025 to 2030) |
| Largest segment | Peptides and proteins |
| Fastest growing segment | RNAi-based Therapeutics |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Peptides and Proteins, Vaccines, Monoclonal Antibodies, RNAi-based Therapeutics |
| Key market players worldwide | Kamada, MannKind, Ab Initio, Ocugen, CanSino Biologics Inc Class H, AstraZeneca PLC |
Other key industry trends
- In terms of revenue, Japan accounted for 5.4% of the global inhalable biologics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China inhalable biologics market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 539.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Inhalable Biologics Market Scope
Inhalable Biologics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Ocugen | View profile | 51-100 | Malvern, Pennsylvania, United States, North America | http://ocugen.com |
| Ab Initio | View profile | 501-1000 | Lexington, Massachusetts, United States, North America | http://www.abinitio.com |
| MannKind | View profile | 501-1000 | Valencia, California, United States, North America | http://mannkindcorp.com |
| Kamada | View profile | 101-250 | Ness Ziona, HaMerkaz, Israel, Asia | http://kamada.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| CanSino Biologics Inc Class H | View profile | 1494 | 185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, China, People's Republic of, | https://www.cansinotech.com |
Japan inhalable biologics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inhalable biologics market will help companies and investors design strategic landscapes.
Peptides and proteins was the largest segment with a revenue share of 35.36% in 2024. Horizon Databook has segmented the Japan inhalable biologics market based on peptides and proteins, vaccines, monoclonal antibodies, rnai-based therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
Japan’s market is expanding due to government funding for peptide and protein-based biologics research and increasing focus on aging-related respiratory conditions.
Hospital pharmacies remain the dominant distribution channel, with retail pharmacies enhancing access to chronic disease treatments.
Reasons to subscribe to Japan inhalable biologics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan inhalable biologics market databook
-
Our clientele includes a mix of inhalable biologics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan inhalable biologics market , including forecasts for subscribers. This country databook contains high-level insights into Japan inhalable biologics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Japan inhalable biologics market size, by type, 2018-2030 (US$M)
Japan Inhalable Biologics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
